MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease.

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) causes selective destruction of dopaminergic neurons of the nigrostriatal pathway in humans and other primates. It is less specific and much less potent in mice and has only slight effects in rats. Differences in rates and sites of metabolism of MPTP to its active, toxic, highly polar metabolite, MPP+ (1-methyl-4-phenylpyridine), appear to influence species specificity. In rats, type B monoamine oxidase (MAO-B), which mediates the conversion of MPTP to MPP+, may act as an enzymatic barrier at brain microvessels, whereas in primates the enzyme, present mainly in astrocytes, appears important for bioactivation of MPTP into the toxic metabolite. MPP+ is a substrate for catecholamine uptake sites and is concentrated in these neurons. The molecular mechanism of MPP+ toxicity has not been established definitively, but conversion to a free radical or uptake by mitochondria and inhibition of mitochondrial respiratory enzymes, leading to calcium release and cell death have been suggested. The discovery of toxin which causes an animal model of Parkinson's disease has stimulated new research on environmental factors that might contribute to this progressive degenerative disorder and provides a means for assessing new approaches to therapy.

[1]  R. M. Rose,et al.  Distinct monoamine oxidase A and B populations in primate brain. , 1985, Science.

[2]  J. Vitorica,et al.  Impairment of glutamate uptake and absence of alterations in the energy-transducing ability of old rat brain mitochondria , 1985, Mechanisms of Ageing and Development.

[3]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[4]  C. Mytilineou,et al.  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. , 1984, Science.

[5]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[6]  D. Jacobowitz,et al.  Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.

[7]  E. Sundström,et al.  Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. , 1985, European journal of pharmacology.

[8]  S. Snyder,et al.  Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. , 1984, European journal of pharmacology.

[9]  A. J. Bradbury,et al.  The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice antagonism by monoamine oxidase inhibitors Antagonism by monoamine oxidase inhibitors , 1986, Neuropharmacology.

[10]  R. Ramsay,et al.  Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. , 1986, The Journal of biological chemistry.

[11]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[12]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[13]  A. Carlsson,et al.  Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain , 1985, Neuropharmacology.

[14]  R. Ramsay,et al.  Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. , 1986, Life sciences.

[15]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. J. Bradbury,et al.  The neurotoxic actions of 6-hydroxydopamine infused into the rat substantia nigra , 1986, Neuroscience Letters.

[17]  R. Duvoisin.  Is Parkinson’s Disease Acquired or Inherited? , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[18]  S. Snyder,et al.  Neuromelanin: a role in MPTP-induced neurotoxicity. , 1987, Life sciences.

[19]  M. Jarvis,et al.  Age-dependent effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) , 1985, Neuropharmacology.

[20]  B. Frei,et al.  N‐Methyl‐4‐phenylpyridine (MMP+ together with 6‐hydroxydopamine or dopamine stimulates Ca2+ release from mitochondria , 1986, FEBS letters.

[21]  D. D. Di Monte,et al.  Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity. , 1986, Biochemical and biophysical research communications.

[22]  V. Yong,et al.  Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment , 1986, Neuroscience Letters.

[23]  S. Finklestein,et al.  Antioxidants fail to inhibit depletion of striatal dopamine by MPTP , 1986, Neurology.

[24]  H. Pakkenberg,et al.  The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, The New England journal of medicine.

[25]  E. Melamed,et al.  Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) , 1986, Neuroscience Letters.

[26]  R. Ramsay,et al.  Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. , 1986, Biochemical and biophysical research communications.

[27]  R. Clavier,et al.  Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse , 1985, Neuroscience Letters.

[28]  J. Langston,et al.  Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum , 1985, Neuroscience Letters.

[29]  J. Cadet,et al.  Role of N-methyltransferases in the neurotoxicity associated with the metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and other 4-substituted pyridines present in the environment. , 1986, Biochemical pharmacology.

[30]  P. Ballard,et al.  Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s Disease , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[31]  R. Fariello,et al.  Effect of 1-methyl-4-phemyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse , 1986, Neuropharmacology.

[32]  B. Parsons,et al.  Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]parygyline binding to monoamine oxidase , 1985, Brain Research.

[33]  B. Goldstein,et al.  Decrease in mouse lung and liver glutathione peroxidase activity and potentiation of the lethal effects of ozone and paraquat by the superoxide dismutase inhibitor diethyldithiocarbamate. , 1979, Biochemical pharmacology.

[34]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[35]  J. Langston,et al.  Pargyline prevents MPTP-induced parkinsonism in primates. , 1984, Science.

[36]  A. Sahgal,et al.  N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat , 1984, Neuroscience Letters.

[37]  J. Vitorica,et al.  Involvement of mitochondria in the age-dependent decrease in calcium uptake of rat brain synaptosomes , 1986, Brain Research.

[38]  J. Langston,et al.  Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? , 1985, Life sciences.

[39]  R. Heikkila.  Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. , 1985, European journal of pharmacology.

[40]  L. Olson,et al.  Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57 BL/6 mice. Comparison with three other strains of mice , 1987, Brain Research.

[41]  S. Markey,et al.  1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. , 1986, Life sciences.

[42]  C. Marsden,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset , 1984, Neuroscience Letters.

[43]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[44]  J. Langston,et al.  1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra , 1984, Neuroscience Letters.

[45]  J. Poirier,et al.  1-Methyl-4-phenyl-pyridinium-induced inhibition of nicotinamide adenosine dinucleotide cytochrome c reductase , 1985, Neuroscience Letters.

[46]  S. Markey,et al.  Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. , 1984, European journal of pharmacology.

[47]  S. Snyder,et al.  Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.

[48]  I. Kopin,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. , 1985, European journal of pharmacology.

[49]  G. Krishna,et al.  Formation of superoxide and hydroxyl radicals from 1-methyl-4-phenylpyridinium ion (MPP+): reductive activation by NADPH cytochrome P-450 reductase. , 1986, Biochemical and biophysical research communications.

[50]  V. Yong,et al.  Manipulation of glutathione contents fails to alter dopaminergic nigrostriatal neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse , 1986, Neuroscience Letters.

[51]  W. Nicklas,et al.  Studies on the Neurotoxicity of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine: Inhibition of NAD‐Linked Substrate Oxidation by Its Metabolite, 1‐Methyl‐4‐Phenylpyridinium , 1986, Journal of neurochemistry.

[52]  U. Bonuccelli,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde. , 1987, Life sciences.

[53]  S. Snyder,et al.  II. Neuromelanin: A role in MPTP-induced neurotoxicity , 1987 .